Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, ...

We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Dancing the Blues Away' Seen in Brain Imaging in People With Parkinson's Disease, New Study Finds Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the ...

physiology, anatomy and pharmacology of the nervous system, as well as computational, behavioural and cognitive neuroscience. During the pathogenesis of Parkinson’s disease (PD), α-synuclein ...

Parkinson's disease is a progressive disorder that develops when the brain cells that produce dopamine (a chemical involved in movement) stop working or die. When this happens, symptoms like slowed ...

More than one million people in the UK are affected by Parkinson’s disease including families and friends of people with a diagnosis. There are currently around 145,000 people with Parkinson’s disease ...